June 12, 2018 — IsoRay Inc. announced the initiation of research funding for brain cancer treatment to Ochsner Clinic Foundation, a not-for-profit health system based in Louisiana.
The funding is intended to support a study entitled “Comparison of Minimally Invasive Keyhole Craniotomy and Stereotactic Radiosurgery for the Treatment of New Brain Oligometastases: A Prospective, Open Label Study.” The study will be led by Marcus Ware M.D., Ph.D., medical director of neurosurgical oncology at Ochsner. Ware is a Harvard Medical School graduate who completed his residency at the University of California, San Francisco, one of the premiere programs in the world in brain tumor surgery and neuro-oncology. At Ochsner, he specializes in the treatment of primary and metastatic brain tumors.
Ware has actively pursued therapies that effectively address various brain cancers while minimizing impact on quality-of-life throughout his career. This new study will explore IsoRay’s signature Cesium-131 brachytherapy seed placed at the time of a brain surgery, a technique known as “keyhole” surgery. The combination of this minimally invasive surgery with Isoray’s highly conformal radiation therapy is intended to provide definitive treatment of brain tumors with surgery and radiation with as little impact on a patient’s quality of life as possible.
For more information: www.isoray.com
April 10, 2026 
